Articles By Eric Dein, MD
Thresholds of Hydroxychloroquine Blood Levels
23 November 2022
Hydroxychloroquine remains the backbone of treatment for SLE, and the only drug clinically proven to decrease mortality. Optimization of usage is therefore critical in maximizing benefit and preventing harms. Hydroxychloroquine blood level testing is available in clinical practice and can help guide this management.
Read Article
Is exercise the missing medicine in lupus?
14 November 2022
For lupus, sedentary lifestyle may be a driving force of disease activity. Today, the final day of ACR, Sarah Patterson, MD from UCSF will present
Read Article
Potential new treatment for Sjogren's
13 November 2022
Is there finally something new on the horizon in Sjogren’s syndrome?
Read Article
Malignancy risk on b/tsDMARDs in patients with prior malignancy history
04 June 2022
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern.
Read Article
Real World Data on Urate Lowering Therapy
04 June 2022
Urate lowering therapy (ULT) is the backbone therapy for long-term gout treatment and maintenance, but real-world gout management is often imperfect and suboptimal.
Read Article
Can "Ultra-low" dose Rituximab work for RA?
11 November 2021
The REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid arthritis. Their study randomized 118 patients with rheumatoid arthritis to 1000 mg, 500 mg, and "ultra-low" dose 200 mg.
Read Article
After failing a JAK inhibitor, can you still hit a JAK-pot?
08 November 2021
Januse kinase (JAK) inhibitors are targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) that have risen in popularity as earlier treatment options for rheumatoid arthritis.
Read Article
Can the Focus Score predict Lymphoma in Sjogren’s syndrome?
08 June 2021
Patients with Sjogren’s syndrome are nearly 19 times more likely to develop lymphoma, so identifying factors that impact this risk development is a major goal in caring for this disorder.
Read Article
Is Rituximab and Belimumab the Combination to Beat Lupus?
04 June 2021
On day 2 of EULAR conference, Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. B cell depletion with rituximab is common treatment for refractory SLE, though real-world data for rituximab has been uncertain. It is known that B-cell activating factor (BAFF) levels can increase after rituximab, which can lead to disease flares. Using belimumab, a human monoclonal antibody inhibiting BAFF, could be a potential therapeutic option after rituximab infusions.
Read Article
Mortality in Low Dose Prednisone
08 December 2020
Upon release of the new ACR 2020 Pharmacologic Treatment Recommendations for the Management of Rheumatoid Arthritis, many practitioners were surprised that the new guidelines recommended against glucocorticoid initiation at disease onset.
Read Article